Theo Heller MD
Hepatology & Liver Transplantation
Chief, Translational Hepatology Section, NIDDK, NIH.
Join to View Full Profile
8600 Old Georgetown RdBethesda, MD 20814
Phone+1 301-896-3517
Fax+1 301-493-4259
Dr. Heller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandFellowship, Gastroenterology, 1997 - 2000
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1990 - 1993
University of the WitwatersrandClass of 1989
Certifications & Licensure
MD State Medical License 1992 - 2026
Clinical Trials
- Immune Response to Hepatitis C Virus Start of enrollment: 2000 Sep 24
- Pegylated Interferon to Treat Chronic Hepatitis D Start of enrollment: 2001 Aug 01
- Lonafarnib for Chronic Hepatitis D Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- Correction: The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.Prabha Chandrasekaran, Máté Krausz, Yu Han, Noriko Mitsuiki, Annemarie Gabrysch
Microbiome. 2025-03-15 - Roux limb revision for recalcitrant bile reflux after total gastrectomy.Amber F Gallanis, Cassidy Bowden, Disha Sharma, Gracia Viana Rodriguez, Rachael Lopez
Surgery. 2025-02-15 - 2 citationsThe intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.Prabha Chandrasekaran, Máté Krausz, Yu Han, Noriko Mitsuiki, Annemarie Gabrysch
Microbiome. 2025-02-11
Journal Articles
- Characterization of the Hepatosplenic and Portal Venous Findings in Patients with Proteus SyndromeTheo Heller, MD, American Journal of Medical Genetics Part A
- Rheological Determinants for Simultaneous Staging of Hepatic Fibrosis and Inflammation in Patients with Chronic Liver DiseaseAhmed M Gharib, Theo Heller, NMR in Biomedicine
Press Mentions
FDA Rejects Full Approval of Liver Disease DrugNovember 12th, 2024- Approved Liver Disease Drug Has No Clinical Benefit, FDA Panel SaysSeptember 13th, 2024
- FDA Summit on Gene Therapy Risks Proves TimelySeptember 7th, 2021
- Join now to see all
Grant Support
- Investigation of non-cirrhotic portal hypertension.NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESPresent
- Investigation of management and disease manifestations of viral hepatitisNATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESPresent
- Investigation of management and disease manifestations of viral hepatitisNATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESPresent
- Investigation of non-cirrhotic portal hypertension.NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
